Publishing date
- 23 October 2026
KaLy-Cell (GIVIMP) is committed to advancing hepatotoxicity and endocrine disruptor R&D (EATS battery) through New Approach Methodologies for over 20 years. Guided by our values of adaptability, collaboration, and tailored approaches, we support our customers in supporting the development and regulatory approval of drugs, cosmetics, food additives, (agro)chemicals, and nutraceuticals. Our services include a wide range of in vitro studies for testing across all species (human and animal).